Chembio Diagnostics Inc. has won a $330,000 federal contract to supply its rapid tests for three mosquito-borne viruses, including Zika, for use in four foreign countries, executives said Wednesday.
The Medford-based manufacturer said it would provide point-of-care tests and results monitors to the federal Centers for Disease Control and Prevention as part of a “surveillance testing program” in Guatemala, Haiti, India and Peru.
One of the tests detects Zika and the other detects Zika, Chikungunya and Dengue. Both use blood samples and produce results in about 15 minutes.
“We are thrilled that CDC has chosen Chembio as a partner in the fight against the Zika virus,” said Chembio CEO John J. Sperzel. “We believe this pilot program will demonstrate the ability of [Chembio’s tests] to discriminate among the viruses, identify co-infected patients, and limit the spread of these serious, life-threatening diseases.”
The announcement was made before the stock market opened. In early trading, Chembio shares were down 3 cents, or less than 1 percent, to $7.06 on the Nasdaq stock market.